TAGRISSO ® (osimertinib) mengurangi risiko kemajuan penyakit atau kematian sebesar 84% pada pasien kanker paru-paru Stadium III EGFR-mutasi yang tidak dapat dioperasi dibandingkan dengan plasebo dalam uji coba Fase III LAURA.
The LAURA Phase III trial results represent a significant advancement in the treatment of Stage III EGFR-mutated non-small cell lung cancer. TAGRISSO demonstrated a remarkable improvement in progression-free survival, reducing the risk of disease progression or death by 84% compared to placebo. This groundbreaking data establishes TAGRISSO as a new standard of care for patients … Baca Selengkapnya